Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe
Fredrik Schjesvold, MD, PhD
Head of Oslo Myeloma Center
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo
Jar, Akershus, Norway